News Releases

Month Year

Jan 27, 2016

RegeneRx's TB4 Shown to Promote Regeneration and Repair of Damaged Central Nervous System Cells

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or the "Company"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced the...
Dec 23, 2015

RegeneRx Joint Venture Posts Results of Severe Dry Eye Trial On ClinicalTrials.gov

Phase 2 Trial Meets Key Efficacy Objectives

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Dec 4, 2015

RegeneRx Receives Chinese Patent for Key TB4 Peptide Fragment

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Oct 28, 2015

RegeneRx Analyst Report Update Issued by SeeThruEquity, LLC

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that SeeThruEquity, LLC's research...
Oct 23, 2015

RegeneRx Updates on Asian Ophthalmic Clinical Trials

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or the "Company"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today is providing...
Oct 21, 2015

RegeneRx Updates on U.S. Ophthalmic Clinical Trials

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or the "Company"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today is providing...
Oct 20, 2015

RegeneRx's TB4 Shown to Significantly Limit Brain Damage After Stroke by Upregulating microRNA-200a

TB4 Increases Stem Cell Survival and Differentiation

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or the "Company"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced a...
Sep 30, 2015

RegeneRx Receives $500,000 Milestone Payment With Enrollment of First Patient in U.S. Phase 2b/3 Dry Eye Trial

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or the "Company"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Sep 21, 2015

RegeneRx Announces First Patient Enrolled in Phase 3 U.S. Neurotrophic Keratopathy (NK) Clinical Trial with RGN-259

Data Expected in Early 2016

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced today that...
Sep 16, 2015

RegeneRx Announces First Patients Enrolled in Phase 2b/3 U.S. Dry Eye Clinical Trial with RGN-259

Data Expected in Early 2016

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced today that...

Show per page